Abbvie Inc Stock Price, News & Analysis

Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) announces participation in a live investor webinar focused on Duchenne muscular dystrophy (DMD) on December 4, 2024, at 2:00 pm ET. The webinar will feature key opinion leaders discussing three main topics: new treatment approaches for DMD, patient navigation of clinical trials, and Satellos' novel small molecule approach focusing on muscle regeneration.

Featured speakers include Elijah Stacy, a DMD patient advocate and Founder of Destroy Duchenne, Dr. Michael Rudnicki, Scientific Founder of Satellos and Director of Regenerative Medicine at Ottawa Hospital Research Institute, and Dr. Jordan Dubow, Satellos' CMO. The event will include a Q&A session and is free to attend.

AbbVie (NYSE: ABBV) has announced its participation in Citi's 2024 Global Healthcare Conference scheduled for Tuesday, December 3, 2024. The company will be represented by three executive leaders: Scott T. Reents (CFO), Jeffrey R. Stewart (CCO), and Dr. Roopal Thakkar (EVP of R&D and CSO), who will present at 9:15 a.m. Central time.

The presentation will be accessible via live audio webcast through AbbVie's Investor Relations website, with an archived version available later that day.

Allergan Aesthetics, an AbbVie company, has launched AMI Business Education, offering free online business training courses through the AMI Online platform. The initiative includes seven new e-trainings, each under 30 minutes, designed to help healthcare practitioners enhance their practice management with Allergan Aesthetics products. The curriculum covers key areas including practice success ingredients, goal setting, telephone lead conversion, and patient partnership development. The program aims to support practitioners in balancing clinical excellence with business operations, providing practical tools for sustainable growth and practice management efficiency.

AbbVie (ABBV) has received European Commission approval for ELAHERE® (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer in adult patients with folate receptor-alpha positive disease who have received one to three prior systemic treatments. This marks the first FRα-directed antibody drug conjugate approved in the EU and associated regions.

The approval is supported by the Phase 3 MIRASOL trial results, which showed a 35% reduction in tumor progression or death risk and a 33% reduction in death risk compared to chemotherapy. The companion diagnostic VENTANA FOLR1 RxDx Assay also received CE Mark approval to identify eligible patients.

AbbVie (NYSE: ABBV) has announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, supporting career aspirations of people living with migraine. The winners, selected through essay, video, and audio submissions, represent diverse professions including engineers, scientists, teachers, and artists. The initiative addresses the significant impact of migraine on careers, noting that nearly 40 million Americans live with this debilitating neurological disease, resulting in over 113 million work days lost annually in the U.S. Winners will receive support to pursue their professional goals while managing migraine symptoms, demonstrating that career ambitions can extend beyond the disease's impact.

AbbVie (NYSE: ABBV) announced that its Phase 2 EMPOWER trials for emraclidine, investigating its use as a once-daily oral treatment for schizophrenia, did not meet their primary endpoint. The trials failed to demonstrate statistically significant reduction in PANSS total scores compared to placebo at week 6. Despite the disappointing results, the drug was well-tolerated with a safety profile similar to Phase 1b trials. Common adverse events included headache (9.4-14.6%), dry mouth (0.8-9.3%), and dyspepsia (1.5-7.8%). The company continues to analyze data to determine next steps while maintaining its commitment to developing treatments for psychiatric and neurological disorders.

Allergan Aesthetics announces its sixth annual BOTOX® Cosmetic Day on November 20, featuring exclusive offers through the Allē rewards program. Following last year's record-breaking gift card sales, this year's celebration includes a Buy-One-Get-One Free gift card offer ($50 value), a Refer-a-Friend promotion worth $50, and a chance to win $10,000.

BOTOX® Cosmetic recently received FDA approval for treating platysma bands, making it the first neurotoxin with four aesthetic indications, including forehead lines, frown lines, and crow's feet lines. The Allē program serves over seven million members across nearly 30,000 practices, offering rewards on various aesthetic treatments and flexible payment options.

Lauren White has been appointed as Chief Financial Officer of Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on neuropsychiatric medicines. White previously served as CFO at ImmunoGen, where she played a important role in the company's $10.1 billion acquisition by AbbVie in 2024 and the commercial launch of ELAHERE®. With over 22 years of experience, White's background includes positions at C4 Therapeutics, Novartis, Boston Consulting Group, and General Electric. She holds a BS from Boston College and an MBA from Harvard Business School.

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific biologics for cancer treatment. The partnership combines AbbVie's oncology expertise with EvolveImmune's proprietary EVOLVE T-Cell Engager Platform, designed to deliver potent T-cell co-stimulation to enhance tumor-killing capacity.

The agreement includes $65 million in upfront fees and equity investment from AbbVie, with potential earnings of up to $1.4 billion in option fees and milestones, plus tiered royalties on net sales. The platform aims to overcome therapeutic challenges in solid and hematologic tumors by bypassing low tumor immunogenicity and reducing T-cell dysfunction.